Neuroscience research has been revolutionized by the use of recombinant viral vector technology from the basic, preclinical and clinical levels. Currently, multiple recombinant viral vector types are employed with each having its strengths and weaknesses depending on the proposed application. Helper-dependent adenoviral vectors (HdAd) are emerging as ideal viral vectors that solve a major need in the neuroscience field: (1) expression of transgenes that are too large to be packaged by other viral vectors and (2) rapid onset of transgene expression in the absence of cytotoxicity. Here, we describe the methods for large-scale production of HdAd viral vectors for in vivo use with neurospecific transgene expression.
You may also like
New approach reveals structure and function of...
December 16, 2020Max Planck Florida Institute for Neuroscience
Targeting Functionally Characterized Synaptic...
December 15, 2020Max Planck Florida Institute for Neuroscience
Charting the developing brain
December 3, 2020Max Planck Institute for Brain Research
Molecular break on learning: uncovering a potential...
November 30, 2020Max Planck Florida Institute for Neuroscience
Proteins in motion
November 18, 2020Max Planck Institute for Brain Research
From the inside out – how the brain forms sensory...
November 13, 2020Max Planck Institute for Brain Research